MAPT and Alzheimer disease: Immunostaining with the conformation-specific antibody for PAD-exposed tau (TNT1) and the neuronal β-III tubulin (Tuj1) antibody (Fig. 2A–C) demonstrated a progressive increase in PAD-exposed tau inclusions over time (DIV 14-31) in AD-tau treated neurons (Fig. 2C and D).